Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Stock Information for Serina Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Serina Therapeutics Inc.

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors
Serina Therapeutics Announces Sale of UniverXome Subsidiary
Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors
Serina Therapeutics to Present at Tribe Public's Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024
Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit
Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.